La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Celularity a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Celularity..

Celularity (NASDAQ:CELU) Azioni, Catena delle Opzioni

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.

Earnings

Earnings Beats

News

LPCN

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

Guidance

FSTR

L.B. Foster Sees FY 2024 Net Sales $530M-$540M Vs $540.92M Est.

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Price Target

Reiteration

Analyst Ratings

JAZZ

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

General

COEP

Coeptis Therapeutics Announces Phase 1 Data On DVX201 For COVID-19 Treatment Has Been Accepted For Publication in 'Molecular Therapy Methods and Clinical Development'

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Guidance
<ul>
<li>Q4 Consolidated Revenue expected to increase in the high-single digits</li>
<li>Full Year 2024 Consolidated Revenue expected to increase in the mid-single digits</li>
<li>Q4 Consolidated Adjusted EBITDA expected to be approximately $290 million, up approximately 39%</li>
<li>Full Year 2024 Consolidated Adjusted EBITDA expected to be approximately$750 million, up approximately 8%</li>
<li>Full Year 2025 Consolidated Revenue expected to be approximately flat in a non-political year</li>
<li>Full Year 2025 Consolidated Adjusted EBITDA3 expected to be approximately$770 million, up approximately 3% in a non-political year</li>
</ul>

IHRT

iHeartMedia Expects Q4 Revenue Growth Of High-Single Digits Vs $1.00B Est, Reiterated FY24 Revenue Growth Of Mid-Single Digits Vs $3.92B Est, FY25 Revenue Growth Of Approx Flat Vs $3.86B Est

Offerings

BYND

Beyond Meat Files To Offer And Sell Common Stock Having Offering Price Of Up To $20M From Time To Time Through Or To Sales Agent

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul>
<li>Dividend Yield: 6.58%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and slashed the price target from $145 to $130 on Aug. 8. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: Copa Holding will release third-quarter results on Nov. 20.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> latest CPA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png" alt="" class="wp-image-634808" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-768x697.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Genco Shipping &amp; Trading Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>)</h3>
<ul>
<li>Dividend Yield: 9.54%</li>
<li>Stifel analyst Benjamin Nolan downgraded the stock from Buy to Hold and cut the price target from $26 to $17 on Oct. 23. This analyst has an accuracy rate of 69%.</li>
<li>B. Riley Securities analyst Liam Burke maintained a Buy rating and increased the price target from $27 to $30 on May 10. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 6, Genco Shipping &amp; Trading posted downbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> to latest GNK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png" alt="" class="wp-image-634809" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-768x706.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.40%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold rating and cut the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating ad increased the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Nov. 6, Karat Packaging raised its quarterly dividend from 35 cents to 40 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> trend in KRT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png" alt="" class="wp-image-634810" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-768x702.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li>Jim Cramer: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Biotech

Health Care

QNRX

Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025

Standard BioTools Inc.&nbsp;("Standard BioTools" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.

Management

Standard BioTools Appoints Alex Kim As Chief Financial Officer, Effective November 11, 2024

OKLO

Oklo Says Department Of Energy And The Idaho National Laboratory Completed Environmental Compliance Process Addressing The DOE Requirements For Site Characterization At Fission Power Plant Site In Idaho

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly sales of $689.000 which missed the analyst consensus estimate of $674.044 million by 100.00 percent. This is a 100.00 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 Sales $689.000 Miss $674.044M Estimate

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Comments

Celularity

Celularity (CELU) Opzioni

Celularity (NASDAQ:CELU) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO